Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HXHongyun Xing

Discussion

Loading...

Member takes

Overview

This analysis demonstrates 100% overall response in CNS DLBCL patients treated with zanubrutinib and rituximab, highlighting potential for improved prognosis.

Key Points

  • Overall response rate was 100%, with 85.7% achieving complete response in patients receiving this regimen.
  • Adverse events included neutropenia (57.1%) and pulmonary infection (42.9%), indicating manageable side effects.
  • The analysis included 7 patients with CNS DLBCL receiving zanubrutinib combined with R + HD-MTX treatment over 4 cycles.
  • Efficacy and safety of the regimen suggest a promising new option for improving patient outcomes in CNS DLBCL.

Cite This Study

Hongyun Xing (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d906https://doi.org/10.1182/blood-2025-7224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025
  2. 2Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).2025
  3. 3Tislelizumab combined with zanubrutinib and high-dose methotrexate in newly diagnosed primary central nervous system DLBCL: A phase 2 study2025
  4. 4Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  5. 5Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study2025